ApoE4 Drives Microglial Lipid Dysregulation in Alzheimer's Disease via Epigenetic Reprogramming of the Asxl1/LXRα-H3K4me3 Axis - PubMed
a day ago
- #Epigenetics
- #ApoE4
- #Alzheimer’s disease
- ApoE4 contributes to microglial lipid dysregulation in Alzheimer's disease through epigenetic changes involving the Asxl1/LXRα-H3K4me3 axis.
- The study highlights the role of ApoE4 in altering lipid metabolism in microglia, which is significant in Alzheimer's disease pathology.
- Research was conducted with ethical approval from Fuzhou University Affiliated Provincial Hospital, adhering to ARRIVE guidelines and NIH standards.
- Key findings suggest that epigenetic reprogramming may be a therapeutic target for Alzheimer's disease.
- The study received funding from multiple Fujian Provincial Science and Technology Innovation Joint Funding Projects and the National Natural Science Foundation of China.